Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study).

Type 1 diabetic patients with varying severity of kidney disease were investigated to create multimetabolite models of the disease process. Urinary albumin excretion rate was measured for 3358 patients with type 1 diabetes. Prospective records were available for 1051 patients, of whom 163 showed progression of albuminuria (8.3-year follow-up), and 162 were selected as stable controls. At baseline, serum lipids, lipoprotein subclasses, and low-molecular weight metabolites were quantified by NMR spectroscopy (325 samples). The data were analyzed by the self-organizing map. In cross-sectional analyses, patients with no complications had low serum lipids, less inflammation, and better glycemic control, whereas patients with advanced kidney disease had high serum cystatin-C and sphingomyelin. These phenotype extremes shared low unsaturated fatty acids (UFAs) and phospholipids. Prospectively, progressive albuminuria was associated with high UFAs, phospholipids, and IDL and LDL lipids. Progression at longer duration was associated with high HDL lipids, whereas earlier progression was associated with poor glycemic control, increased saturated fatty acids (SFAs), and inflammation. Diabetic kidney disease consists of diverse metabolic phenotypes: UFAs, phospholipids, IDL, and LDL may be important in the subclinical phase, high SFAs and low HDL suggest accelerated progression, and the sphingolipid pathway in advanced kidney injury deserves further research.

[1]  A. Rigby,et al.  Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 Diabetes , 2007, Diabetes Care.

[2]  D. Sacks.  A1C Versus Glucose Testing: A Comparison , 2011, Diabetes Care.

[3]  Richard M. Moe,et al.  Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. , 2004, Journal of the American College of Cardiology.

[4]  A. Calle-Pascual,et al.  Polyunsaturated fatty acid consumption may play a role in the onset and regression of microalbuminuria in well-controlled type 1 and type 2 diabetic people: a 7-year, prospective, population-based, observational multicenter study. , 2004, Diabetes care.

[5]  Reino Laatikainen,et al.  Strategies for organic impurity quantification by 1H NMR spectroscopy: Constrained total-line-shape fitting , 2005 .

[6]  Aki Vehtari,et al.  A multi-metabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer's disease. , 2008, Biochemical and biophysical research communications.

[7]  B. Vergès.  Lipid disorders in type 1 diabetes. , 2009, Diabetes & metabolism.

[8]  Aki Vehtari,et al.  A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in 1H NMR metabonomic data , 2007, BMC Bioinformatics.

[9]  K. Kaski,et al.  1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death , 2008, Molecular systems biology.

[10]  Mika Ala-Korpela,et al.  Critical evaluation of 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics , 2008, Clinical chemistry and laboratory medicine.

[11]  M. Mauer,et al.  Enhancing the predictive value of urinary albumin for diabetic nephropathy. , 2006, Journal of the American Society of Nephrology : JASN.

[12]  S. Hofer,et al.  Diabetic Nephropathy in 27,805 Children, Adolescents, and Adults With Type 1 Diabetes , 2007, Diabetes Care.

[13]  K. Musunuru.  Atherogenic Dyslipidemia: Cardiovascular Risk and Dietary Intervention , 2010, Lipids.

[14]  René M. Botnar,et al.  Subclinical Coronary and Aortic Atherosclerosis Detected by Magnetic Resonance Imaging in Type 1 Diabetes With and Without Diabetic Nephropathy , 2006, Circulation.

[15]  S. Yamashita,et al.  Identification of Unique Lipoprotein Subclasses for Visceral Obesity by Component Analysis of Cholesterol Profile in High-Performance Liquid Chromatography , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[16]  G. Dahlquist,et al.  Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: a population-based study in northern Sweden. , 2004, Diabetes care.

[17]  M. Mauer,et al.  The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007 , 2008, Diabetologia.

[18]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Medicine.

[19]  R. Klein,et al.  Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. , 2004, Archives of internal medicine.

[20]  M. Rewers,et al.  Insulin Resistance, Defective Insulin-Mediated Fatty Acid Suppression, and Coronary Artery Calcification in Subjects With and Without Type 1 Diabetes , 2010, Diabetes.

[21]  Jacek Bielawski,et al.  Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. , 2009, American journal of physiology. Endocrinology and metabolism.

[22]  M. Rastaldi,et al.  Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis , 2011, Science Translational Medicine.

[23]  Thomas Meitinger,et al.  Genetic Determinants of Circulating Sphingolipid Concentrations in European Populations , 2009, PLoS genetics.

[24]  L. Fried,et al.  Temporal patterns in overweight and obesity in Type 1 diabetes , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[25]  J. Viikari,et al.  The prevalence of the metabolic syndrome in young adults. The Cardiovascular Risk in Young Finns Study , 2007, Journal of internal medicine.

[26]  K. Kaski,et al.  Network of vascular diseases, death and biochemical characteristics in a set of 4,197 patients with type 1 diabetes (The FinnDiane Study) , 2009, Cardiovascular diabetology.

[27]  C. Forsblom,et al.  Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study) , 2011, Metabolomics.

[28]  G. Hitman,et al.  Systematic review on urine albumin testing for early detection of diabetic complications. , 2005, Health technology assessment.

[29]  J. Gross,et al.  Diabetic nephropathy: diagnosis, prevention, and treatment. , 2005, Diabetes care.

[30]  E. Volpi,et al.  Amino acid metabolism and regulatory effects in aging , 2008, Current opinion in clinical nutrition and metabolic care.

[31]  G. Shulman,et al.  Effect of glucose, independent of changes in insulin and glucagon secretion, on alanine metabolism in the conscious dog. , 1980, The Journal of clinical investigation.

[32]  M. Bewley,et al.  Circulating sphingolipid biomarkers in models of type 1 diabetes , 2011, Journal of Lipid Research.

[33]  K. Boini,et al.  Role of Sphingolipid Mediator Ceramide in Obesity and Renal Injury in Mice Fed a High-Fat Diet , 2010, Journal of Pharmacology and Experimental Therapeutics.

[34]  M. Halperin,et al.  Hyperglycemia-induced hyponatremia: metabolic considerations in calculation of serum sodium depression. , 1975, Canadian Medical Association journal.

[35]  S. Kelsey,et al.  Cause-Specific Mortality Trends in a Large Population-Based Cohort With Long-Standing Childhood-Onset Type 1 Diabetes , 2010, Diabetes.

[36]  Martin Adiels,et al.  Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[37]  M. Kohno,et al.  Metabolomic analysis of human plasma from haemodialysis patients , 2011, European journal of clinical investigation.

[38]  K. Kaski,et al.  Metabolic Phenotypes, Vascular Complications, and Premature Deaths in a Population of 4,197 Patients With Type 1 Diabetes , 2008, Diabetes.

[39]  W. F. Taylor,et al.  Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability , 1970, Diabetes.

[40]  T. Pang,et al.  Addressing insulin resistance in Type 1 diabetes , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[41]  F. Kronenberg,et al.  Long-term mortality and incidence of renal dialysis and transplantation in type 1 diabetes mellitus. , 2006, The Journal of clinical endocrinology and metabolism.

[42]  P. Singer,et al.  Effects of polyunsaturated fatty acid consumption in diabetic nephropathy , 2011, Nature Reviews Nephrology.

[43]  Daniel Raftery,et al.  Quantitative Metabolomics by 1H-NMR and LC-MS/MS Confirms Altered Metabolic Pathways in Diabetes , 2010, PloS one.

[44]  K. Kalantar-Zadeh,et al.  Diets and enteral supplements for improving outcomes in chronic kidney disease , 2011, Nature Reviews Nephrology.

[45]  J. D. Walker,et al.  Microalbuminuria and mortality in long-duration type 1 diabetes. , 2003, Diabetes care.

[46]  E. Agardh,et al.  Nephropathy, but not retinopathy, is associated with the development of heart disease in Type 1 diabetes: a 12‐year observation study of 462 patients , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[47]  S Mierisová,et al.  MR spectroscopy quantitation: a review of frequency domain methods , 2001, NMR in biomedicine.